Initiative for Women with Disabilities Care Team | NYU Langone Health
NYU Langone’s Initiative for Women with Disabilities staff empowers women with physical disabilities to achieve their goals.
Initiative for Women with Disabilities Doctors | NYU Langone Health
Find a doctor at the Initiative for Women with Disabilities at NYU Langone.
Innovative NeurovaScular Product surveIllance REgistry (INSPIRE)
The purpose of this study is to collect information over time about how the approved Pipeline™ Shield Device is working and/or the outcome of the treatment. The study will be used to support post-market surveillance activities and post-approval studies (e.g., to collect safety and performance information). In addition, it will be used to obtain clinical evidence for the development and improvement of medical devices, therapies, device guidelines, patient services/solutions and provide clinical data to support health economics and clinical outcomes research. The Pipeline™ Shield Device is not investigational and the procedures being performed are not experimental.
Inpatient Pediatric Hospitalist Service | NYU Langone Health
Pediatric hospitalists, who are inpatient specialists, care for children at Hassenfeld Children’s Hospital at NYU Langone.
Inpatient Psychiatry at Tisch Hospital | NYU Langone Health
Voluntary inpatient psychiatric care from our highly trained psychiatrists and therapists is available at NYU Langone’s Tisch Hospital.
Inpatient Psychiatry at Tisch Hospital Doctors | NYU Langone Health
Find a doctor at the Inpatient Psychiatry at Tisch Hospital at NYU Langone.
Inpatient Treatment for Glomerulonephritis in Children | NYU Langone Health
Specialists at Hassenfeld Children’s Hospital at NYU Langone offer various in-hospital treatments for children with severe glomerulonephritis.
Insomnia and its association with Peripheral Neuropathy and Myasthenia Gravis(MG)
Insomnia and NeuropathyNeuropathic pain and chronic pain is associated with sleep disturbances suggesting that increased pain sensitivity and sleep disturbance have a complex relationship. Importantly, insomnia is modifiable with targeted psychological interventions. Thus, strategies to identify and modify sleep may improve neuropathic pain symptoms, quality of life, and sleep duration. This may be especially necessary in diabetic populations with a high incidence of peripheral neuropathy and older patients for which pharmacologic treatments are sub-optimal or intolerable.Insomnia is a disturbance of sleep continuity associated with daytime complaints related to sleepiness, fatigue, somatic symptoms (e.g., headaches or body aches), mood and cognitive changes, impaired occupational function, concerns about sleep, or dissatisfaction with sleep. Insomnia is estimated to occur in up to a third of the adult population worldwide and primary care practices report upwards of 50% prevalence of insomnia in outpatients. Insomnia is often comorbid with other medical conditions (e.g., cardiometabolic diseases and depression), and is often reported as a symptom associated with peripheral neuropathy.Insomnia and MG Insomnia and difficulty sleeping has been reported in patients with Myasthenia Gravis (MG) and as a contributing factor to the fatigue that is often reported in this immune mediated neuromuscular disease.29 Chronic use of corticosteroids for immunosuppression has been associated with insomnia in patients with MG.29,30 In one study that examined sleep outcomes, in 54 patients with MG, 60% of participants had a Pittsburgh Sleep Quality Index (PSQI) score that was pathological (PSQI > 5).30 When these patients were further stratified those with more severe clinical MG had worse scores compared to those in clinical remission (pathological PSQI score was found in 82.6% of patients in the generalized category, 50% in the ocular category and 40% in the remission category) suggesting that disease severity may also be a factor related to impaired sleep in MG.30 In a larger population-based study out of Denmark, participants who responded to an online survey regarding fatigue and level of physical activity had elevated insomnia severity index (ISI) scores.31In addition to insomnia excessive daytime sleepiness has been reported in MG.30,32,33Excessive daytime sleepiness and clinically worse MG is associated with obstructive sleep apnea (OSA) with the population prevalence of OSA in MG being greater than in the general population (36% compared to an expected prevalence of 15 to 20% in the general population).32 However excessive daytime sleepiness as measured by the ESS is also reported in people with MG in clinical remission.30As mentioned above, insomnia is highly prevalent in the United States and regardless of whether insomnia is a primary medical condition or associated with another co-morbid disease, the American College of Physicians (ACP) recommends that treatment for insomnia with cognitive behavioral therapy-insomnia (CBT-I) to improve sleep health should be provided regardless of the presence or absence of any comorbid illnesses that could have precipitated the insomnia.10 CBT-I may also help reduce insomnia symptoms even when co-morbid with other sleep disorders.16 It is unclear if an intervention like CBT-I could improve MG symptoms and fatigue associated with MG. People with neuropathy sometimes can also utilize complimentary and integrative therapies (CIT). Since the global pandemic, there has been a proliferation of mindfulness-based applications and virtual psychotherapy along with vitamins and supplements that some people with neuropathy may be utilizing. Some people have also been receiving acupuncture and massage and physical therapy to compliment their treatments as well. Our goal is to assess what types of CIT our patients are utilizing in addition to pharmacological therapies that we prescribe for patients with peripheral neuropathy.
Insurance, Billing & Financial Assistance | NYU Langone Health
Find out more about insurance coverage, billing, and financial assistance at NYU Langone Health.
Integrated multi-omics approaches to precision medicine in kidney disease (iMAP-Kidney)
The primary objective of the study is to establish a biorepository (tissue bank) for the storage of plasma, serum, DNA, RNA, urine, and fresh tissue from kidney and kidney allograft biopsies, from patients undergoing kidney biopsy. This objective will be accomplished through the following: 1) establishing a clinical registry containing information linked from the patient’s medical record; 2) digitizing kidney histology slides from kidney tissue biopsies; 3) obtaining leftover archival tissue if extra fresh tissue collection is deemed unsafe by the physician, if the patient is pregnant, or if the patient refuses extra tissue collection and 4) allowing for accessibility to newly obtained samples for related studies.